Hemorrhage rates and outcomes when using up to 100 mg intra-arterial t-PA for thrombolysis in acute ischemic stroke

Interventional Neuroradiology

Volumn 16, Issue 3, 2010, Pages 297-305

  Christoforidis, Gregory A ^a   Slivka, A P ^b   Karakasis, C ^b   Mohammad, Y ^c   Avutu, B ^b   Yang, M ^b   Bourekas, E C ^b   Chakeres, D W ^b   Slone, H W ^b   Yuk, W T ^b  

^a UNIVERSITY OF CHICAGO   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^c RUSH UNIVERSITY   (United States)

Author keywords

Acute ischemic stroke; Intracerebral hemorrhage; Thrombolytic therapy

Indexed keywords

TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; BASILAR ARTERY; BLOOD CLOT LYSIS; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CONTROLLED STUDY; FEMALE; HOSPITAL DISCHARGE; HUMAN; INTERNAL CAROTID ARTERY; MAJOR CLINICAL STUDY; MALE; MIDDLE CEREBRAL ARTERY; REPERFUSION; THROMBOCYTE COUNT;

EID: 78649455226     PISSN: 15910199     EISSN: None     Source Type: Journal    
DOI: 10.1177/159101991001600312     Document Type: Article

References (37)

1. The National Institute of Neurological Disorders and Stroke (NINDS) Trial. NEJM. 1995; 33: 1581-1587.
2. Kidwell CS, Saver JL, Carnado J, et al. Predictors of hemorrhagic transformation in patients receiving intra-arterial thrombolysis. Stroke. 2002; 33: 717.
3. Furlan A, Higashida R, Weschler L, et al. Intra-arterial prourokinase for acute ischemic stroke:the PROACT II study. JAMA. 1999; 282: 2003-2011.
4. Del Zoppo G, Higashida R, Furlan A, et al. PROACT: A phase ii randomized trial of recombinant pro-urokinase by direct arterial delivery in acute middle cerebral artery stroke. Stroke. 1998; 29: 4-11.
5. Kase C, Furlan AJ, Weschler L, et al. Cerebral hemorrhage after intra-arterial thrombolysis for ischemic stroke:The PROACT II Trial. Neurology. 2001; 57: 1603-1610.
6. Lisboa RC, Javanovic BD, Alberts MJ. Analysis of the safety and efficacy of intra-arterial thrombolytic therapy in ischemic stroke. Stroke. 2002; 33: 2866-2871.
7. Von Kummer R, Hacke W. Safety and efficacy of intravenous tissue plasminogen activator and heparin in acute middle cerebral artery stroke. Stroke. 1992; 23: 646-652.
8. Levy D, Brott T, Haley C, et al. Factors related to intracranial hematoma formation in patients receiving tissue-type plasminogen activator for acute ischemic stroke. Stroke. 1994; 25: 291-297.
9. Del Zoppo G, Poeck K, Pessin M, et al. Recombinant tissue plasminogen activator in acute thrombotic and embolic stroke. Ann Neurol. 1992; 32: 78-86.
10. Clark WM, Wissman S, Albers GW, et al. Recombinant tissue-type plasminogen activator (alpteplase) for ischemic stroke 3 to 5 hours after symptom onset: The ATLANTIS Study. JAMA. 1999; 282: 2019-2026.
11. The NINDS t-PA Stroke Study Group. Intracerebral hemorrhage after intravenous t-pa therapy for ischemic stroke. Stroke. 1997; 28: 2109-2118.
12. Hacke W, Kaste M, Fieschi C, et al. Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke: The European Cooperative Acute Stroke Study (ECASS). JAMA. 1995; 274: 1017-1025.
13. Jaillard A, Cornu C, Durieux A. Hemorrhagic transformation in acute ischemic stroke: the MAST-E study. Stroke. 1999; 30: 1326-1332.
14. Larrue V, von Kummer R, del Zoppo G, et al. Hemorrhagic transformation in acute ischemic stroke potential contributing factors in the European Cooperative Acute Stroke Study. Stroke. 1997; 28: 957-960.
15. Demchuk A, Morgenstern L, Krieger D, et al. Serum glucose level and diabetes predict tissue plasminogen activator-related intracerebral hemorrhage in acute ischemic stroke. Stroke. 1999; 30: 34-39.
16. Selim M, Fink JN, Kumar S, et al. Predictors of hemorrhagic transformation after intravenous recombinant tissue plasminogen activator: prognostic value of the initial apparent diffusion coefficient and diffusion-weighted lesion volume. Stroke. 2002; 33: 2047-2052.
17. Christoforidis GA, Mohammad Y, Kehagias D, et al. Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. Am. J. Neuroradiol. 2005; 26: 1789-1797.
18. Theron J, Coskun O, Huet H, et al. Local intraarterial thrombolysis in the carotid territory. Interventional Neuroradiology 1996; 2: 111-126.
19. Liebeskind DS. Collaterals in acute stroke: Beyond the clot. Neuroimaging Clin N Am. 2005; 15: 553-573.
20. Higashida RT, Furlan AJ. Trial design and reporting standards for intra-arterial cerebral thrombolysis for acute ischemic stroke. Stroke. 2003; 34: 109-137.
21. Khatri P, Neff J, Broderick JP, et al. and for the IMS-I Investigators. Revascularization end points in stroke interventional trials: recanalization versus reperfusion in IMS-I. Stroke. 2005; 35: 2400-2403.
22. Hacke W, Kaste M, Fieschi C, et al. Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). Lancet. 1998; 353: 1245-1251.
23. Suarez J, Sunshine J, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 1999; 30: 2094-2100.
24. Slivka A, Christoforidis G, Bourekas E, et al. Clinical and imaging outcomes after stroke with normal angiograms. AJNR. 2005; 26: 242-245.
25. Albers GW, Clark WM, Madden KP, et al. ATLANTIS Trial: For patients treated within 3 hours stroke onset. Stroke. 2002; 33: 493-496.
26. Suarez J, Sunshine J, Tarr R, et al. Predictors of clinical improvement, angiographic recanalization, and intracranial hemorrhage after intra-arterial thrombolysis for acute ischemic stroke. Stroke. 1999; 30: 2094-2100.
27. Baron J, von Kummer R, del Zoppo G. Treatment of acute ischemic stroke: challenging the concept of a rigid and universal time window. Stroke. 1995; 26: 2219-2221.
28. Weir C, Murray G, Dyker A, et al. Is hyperglycemia an independent predictor of poor outcome after acute stroke: Results of a long term follow up study. BMJ. 1997; 314: 1303-1306.
29. Christoforidis GA, Karakasis C, Mohammad YM, et al. Predictors of hemorrhage following intra-arterial thrombolysis for acute ischemic stroke: the role of pial collateral formation Am J Neuroradiol. 2009; 30: 165-170.
30. Christoforidis GA, Slivka A, Mohammad Y, et al. Size matters: hemorrhage volume as an objective measure to define significant intracranial hemorrhage associated with thrombolysis. Stroke. 2007; 38: 1799-1804.
31. Norman GR, Streiner DL. Biostatistics: the bare essentials. Hamilton, Ontario: B.C. Decker Inc.; 2000.
32. Alsop DC, Makovetskaya E, Kumar S, et al. Markedly reduced apparent blood volume on bolus contrast magnetic resonance imaging as a predictor of hemorrhage after thrombolytic therapy for acute ischemic stroke. Stroke. 2005; 36: 746-750.
33. Hacke W, Kaste M, Bluhmki E, et al. Thrombolysis with alteplase 3 to 4.5 hours after acute ischemic stroke. N Engl J Med. 2008; 359: 1317-1329.
34. Fischer S, Kohnert U. Major mechanistic differences explain the higher clot lysis potency of reteplase over alteplase: lack of fibrin binding is an advantage for bolus application of fibrin-specific thrombolytics. Fibrinolysis Proteolysis. 1997; 11: 129-135.
35. Alteplase, recombinant package insert (Activase, Genentech-US), Rev 11/87, Rec 12/87; Rev 6/96, Rec 6/96.
36. Kurz MA. Pharmacology and clot: immediate and chronic interventions. In: Eds. Wakhloo AK, Gounis MJ, Lieber BB, et al. Thrombus and stroke. New York, NY: Informa Health Care U.S.A. Inc.; 2008. p. 103-122.
37. Tomsick T, Barsan W, Brott T, et al. Prognostic value of the hyperdense middle cerebral artery sign and stroke scale score before ultraearly thrombolytic therapy. Am J Neuroradiol. 1996; 17: 79-85.